Drugs / TheraCal PT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07864181 | Jan 2024 → Jun 2025 | pulpitis | Hama University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04167943 | Nov 2019 → Aug 2021 | pulpitis | Ain Shams University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04617600 | Mar → Jun 2022 | pulpitis | Cairo University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06880471 Comparator | Dec 2024 → Oct 2025 | pulpitis | Cumhuriyet University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TheraCal PT | “Evaluation of four vital pulp therapies for primary molars using a dual-cured tricalcium silicate (TheraCal PT): one-year results of a non-randomized clinical trial.” PMID 36890738 ↗ Mar 20233“TheraCal PT cement was directly adapted over the radicular pulp stumps and the entire pulpal floor at a uniform thickness of approximately 2 mm.” NCT07864181 ↗ |
| Known as | ThPT | “TheraCal PT (ThPT, Bisco Inc)” NCT06880471 ↗ |
| Modality | Other / unclassified | “TheraCAL PT, a dual cured tricalcium silicate cement will be used in all groups as the pulp capping material.” NCT04167943 ↗ |